Clarity for US medtech industry on when FDA can 'disapprove' trial applications
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued final guidance to support the timely initiation of medical device trials and to clarify, among other things, the situations in which the FDA cannot disapprove a trial application1,2. When finalizing the guidance, the FDA decided not to go ahead with a proposal for a new voluntary process that would have helped companies determine whether a trial design would lead to market approval of their product.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.